Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist ...
Elevai Labs, Inc. (ELAB)
Company Research
Source: GlobeNewswire
Filed two patent applications for lead candidate EL-22, covering muscle loss in obese patients as a monotherapy and in combination with GLP-1 receptor agonistsElevai Biosciences patent portfolio now includes 4 patent applications and 5 issued patents that provide adequate protection in focus markets NEWPORT BEACH, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) ("Elevai" or the "Company"), a leader in medical aesthetics, today announced the filing of two novel patent applications for its lead candidate, EL-22, aimed at treating muscle loss in obese patients. These patent applications cover both standalone and combination therapies using EL-22 alongside GLP-1 receptor agonists, marking a significant advancement in obesity treatment. The newly filed patent applications support the development of EL-22, an engineered probiotic expressing myostatin, designed to revolutionize obesity care by preserving muscle mass while reducing fat mass. EL-22 has successful
Show less
Read more
Impact Snapshot
Event Time:
ELAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELAB alerts
High impacting Elevai Labs, Inc. news events
Weekly update
A roundup of the hottest topics
ELAB
News
- Elevai Labs Inc. Announces Name Change to PMGC Holdings Inc. and Redomicile to NevadaGlobeNewswire
- Elevai Labs Inc. Announces Anticipated Name Change to PMGC Holdings Inc. and Redomicile to Nevada [Yahoo! Finance]Yahoo! Finance
- Elevai Labs Inc. Announces Anticipated Name Change to PMGC Holdings Inc. and Redomicile to NevadaGlobeNewswire
- Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle PreservationGlobeNewswire
- Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care MarketGlobeNewswire
ELAB
Sec Filings
- 11/26/24 - Form 8-K
- 11/25/24 - Form DEFR14C
- 11/25/24 - Form DEFR14C
- ELAB's page on the SEC website